Clinical Trial Update: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial of cabozantinib for hepatocellular carcinoma refractory to first-line therapy has completed, including non-resectable or metastatic disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED